Demiurge Technologies AG
Demiurge Technologies specializes in creating virtual patients to predict clinical trial outcomes with high accuracy. Their innovative approach has achieved an 84.4% accuracy rate in predicting phase 2 and phase 3 clinical trial results across various therapeutic areas, including COVID-19 and Alzheimer's disease. The company operates on a model that leverages AI and deep learning to simulate human responses to drugs, thereby reducing the need for traditional clinical trials. With a strong focus on immuno-oncology and first-in-class drug predictions, Demiurge is positioned as a leader in the biotech industry, aiming to transform drug development processes.
Demiurge Technologies AG
Demiurge Technologies specializes in creating virtual patients to predict clinical trial outcomes with high accuracy. Their innovative approach has achieved an 84.4% accuracy rate in predicting phase 2 and phase 3 clinical trial results across various therapeutic areas, including COVID-19 and Alzheimer's disease. The company operates on a model that leverages AI and deep learning to simulate human responses to drugs, thereby reducing the need for traditional clinical trials. With a strong focus on immuno-oncology and first-in-class drug predictions, Demiurge is positioned as a leader in the biotech industry, aiming to transform drug development processes.